David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line...
With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate...
SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients
Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory...
Investigational Drug BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic...
Data from an ongoing phase I trial of BLU-285, an oral inhibitor of KIT D816V, in patients with advanced systemic mastocytosis (SM) suggest that...
Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients
Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.